These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 3624100)

  • 1. Responsibilities of university investigators when conducting trials on investigational new animal drugs.
    Parrott JC
    J Anim Sci; 1987 Aug; 65(2):577-80. PubMed ID: 3624100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responsibilities of animal scientists and drug sponsors when conducting research with investigational new animal drugs.
    Knight WM
    J Anim Sci; 1987 Aug; 65(2):581-3. PubMed ID: 3624101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigator responsibilities for clinical research studies: proper staffing can ensure an investigator is compliant.
    Kee AN
    J Med Pract Manage; 2011; 26(4):245-7. PubMed ID: 21506468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The investigator-sponsored IND in clinical trials.
    Haakenson C; Fye CL; Sather MR; Toussaint DJ
    Control Clin Trials; 1987 Jun; 8(2):101-9. PubMed ID: 3608504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Data integrity-conduct of clinical investigations: university investigator perspective.
    Crooker BA; Preston RL; Boyd RD
    J Anim Sci; 1995 Feb; 73(2):622-7; discussion 627-8. PubMed ID: 7601799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding Food and Drug Administration regulatory requirements for an investigational device exemption for sponsor-investigators.
    Holbein ME; Berglund JP
    J Investig Med; 2012 Oct; 60(7):987-94. PubMed ID: 22847340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A program to provide regulatory support for investigator-initiated clinical research.
    Arbit HM; Paller MS
    Acad Med; 2006 Feb; 81(2):146-53. PubMed ID: 16436575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trials in molecular imaging: the importance of following the protocol.
    Trembath L; Opanowski A;
    J Nucl Med Technol; 2011 Jun; 39(2):63-9. PubMed ID: 21565960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liability and new drug studies. Informed consent and clinical trials at the National Institutes of Health.
    Gallelli JF
    J Pharm Technol; 1991; 7(1):9-12. PubMed ID: 10110213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigator Responsibilities in Clinical Research.
    Feehan AK; Garcia-Diaz J
    Ochsner J; 2020; 20(1):44-49. PubMed ID: 32284682
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of data audits in detecting scientific misconduct. Results of the FDA program.
    Shapiro MF; Charrow RP
    JAMA; 1989 May; 261(17):2505-11. PubMed ID: 2704109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The responsibilities of investigators, monitors, and sponsors of clinical studies supporting new animal drug applications. Center for Veterinary Medicine, FDA.
    Schoenemann HM; McCormack JF; Smedley KO
    J Anim Sci; 1995 Feb; 73(2):606-13; discussion 612-3. PubMed ID: 7601797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical investigation of new animal drugs by veterinary practitioners.
    Prater DA; Bertone JJ; Letonja T; Vaughn SD
    J Am Vet Med Assoc; 1996 Jan; 208(2):190-4. PubMed ID: 8567369
    [No Abstract]   [Full Text] [Related]  

  • 14. The conduct of clinical trials and good clinical practices: the sponsor's perspective. Food and Drug Administration.
    Robb EJ; Davis DD; Farrington DO
    J Anim Sci; 1995 Feb; 73(2):614-9; discussion 619-21. PubMed ID: 7601798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Academic investigator-initiated trials and the challenge of sponsor responsibility: the Cologne Sponsor Model.
    Georgias C; Grunow A; Olderog M; May A; Paulus U
    Clin Trials; 2012 Dec; 9(6):781-7. PubMed ID: 23104975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Operation of a radiopharmacy for a clinical trial.
    Norenberg JP; Petry NA; Schwarz S
    Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency.
    Sellers JW; Mihaescu CM; Ayalew K; Kronstein PD; Yu B; Ning YM; Rodriguez M; Williams L; Khin NA
    Ther Innov Regul Sci; 2022 Sep; 56(5):753-764. PubMed ID: 35610469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Financial disclosure by clinical investigators; correction--FDA. Final rule; correction.
    Fed Regist; 1998 Jun; 63(124):35134. PubMed ID: 10180634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. THE IMPACT OF RECENT REGULATIONS OF THE FEDERAL FOOD AND DRUG ADMINISTRATION ON CLINICAL INVESTIGATION OF NEW DRUGS IN DENTISTRY: THE VIEW OF THE CLINICAL INVESTIGATOR.
    KUTSCHER AH; ZEGARELLI EV
    J Oral Ther Pharmacol; 1964 Jul; 1():79-84. PubMed ID: 14204418
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.